Prognostic markers of the CLL cases studied
| Case no. . | CD38, % . | ZAP70, % . | IgVH . |
|---|---|---|---|
| 1 | 53 | 24 | U |
| 2 | 67 | 64 | U |
| 3 | 47 | 99 | U |
| 4 | 37 | 90 | U |
| 5 | 12 | 32 | M |
| 6 | 5 | 25 | M |
| 7 | 30 | 55 | U |
| 8 | 3 | 5 | M |
| 9 | 96 | 89 | U |
| 10 | 9 | 95 | M |
| 11 | 98 | 3 | M |
| 12 | 2 | 1 | M |
| 13 | 57 | 63 | U |
| 14 | 1 | 1 | M |
| 15 | 1 | 11 | M |
| 16 | 3 | 15 | U |
| 17 | 1 | 16 | M |
| 18 | 1 | 1 | M |
| 19 | 6 | 52 | U |
| 20 | 2 | 20 | M |
| Case no. . | CD38, % . | ZAP70, % . | IgVH . |
|---|---|---|---|
| 1 | 53 | 24 | U |
| 2 | 67 | 64 | U |
| 3 | 47 | 99 | U |
| 4 | 37 | 90 | U |
| 5 | 12 | 32 | M |
| 6 | 5 | 25 | M |
| 7 | 30 | 55 | U |
| 8 | 3 | 5 | M |
| 9 | 96 | 89 | U |
| 10 | 9 | 95 | M |
| 11 | 98 | 3 | M |
| 12 | 2 | 1 | M |
| 13 | 57 | 63 | U |
| 14 | 1 | 1 | M |
| 15 | 1 | 11 | M |
| 16 | 3 | 15 | U |
| 17 | 1 | 16 | M |
| 18 | 1 | 1 | M |
| 19 | 6 | 52 | U |
| 20 | 2 | 20 | M |
*U indicates unmutated, M, mutated IgVH genes; Unmutated had less than 2% mutations; mutated had more than 2%.